The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic ...
Denali Therapeutics and Royalty Pharma entered a $275 million royalty funding agreement based on future sales of tividenofusp alfa.
In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...
TipRanks on MSN
Denali Therapeutics secures $275M royalty funding deal
Denali Therapeutics ( ($DNLI) ) has issued an update. On December 4, 2025, Denali Therapeutics entered into a $275 million synthetic royalty ...
Royalty Pharma (RPRX) and Denali Therapeutics (DNLI) announced a $275M synthetic royalty funding agreement based on future net sales of ...
Intolerable risk. That was what came to Todd Keller’s mind when Granite Construction looked at the design-build solicitation from the Federal Highway Administration in 2022 to rebuild a section of ...
Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback